     |
 |
Latest Personal Injury News Celebrex® Joins Vioxx® in Cardiovascular Side Effects
Source:
December 17, 2004
In an announcement today that some Cox-2 inhibitor researchers expected, Pfizer Inc. said its painkiller Celebrex® increased the risk of heart attacks in a study of cancer patients. The study was halted because patients who used Celebrex® over time showed an increased cardiovascular risk. Cardiovascular side effects are serious and may include chest pains, blood clots, heart attacks and stroke. In the Celebrex cancer study, Pfizer indicates Celebrex had more than twice the number of fatal or non-fatal heart attacks compared with those taking a placebo. Celebrex® is in the same class of drugs as Merck & Co.'s withdrawn Vioxx®. Vioxx® was recalled on September 30, 2004. The third member of the Cox-2 inhibitor family, Bextra® is also produced by Pfizer. The company announced that it will be conducting long-term studies on Bextra® due to the unsubstantiated concerns of increased risk of stroke and heart attack in Bextra as well. The media seems to be scrutinizing Pfizer after the company made at least three statements since the Vioxx® recall affirming the safety of Celebrex®. For information on how Goldberg & Osborne can evaluate a potential Celebrex lawsuit, click here.
<< Back to News |